🇪🇺 EBGLYSS in European Union

EMA authorised EBGLYSS on 16 November 2023

Marketing authorisation

EMA — authorised 16 November 2023

  • Application: EMEA/H/C/005894
  • Marketing authorisation holder: Almirall, S.A.
  • Local brand name: Ebglyss
  • Indication: Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
  • Status: approved

Read official source →

EBGLYSS in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is EBGLYSS approved in European Union?

Yes. EMA authorised it on 16 November 2023.

Who is the marketing authorisation holder for EBGLYSS in European Union?

Almirall, S.A. holds the EU marketing authorisation.